SCHEMBL16866232

SCHEMBL16866232

CC(C)C(=O)N1C2CCCC1CC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
CHRM1 P11229 4/20 0.38
CHRNB2 P17787 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA4 P43681 1/20 0.36
CHRNB3 Q05901 1/20 0.36
CHRNA6 Q15825 1/20 0.36
MAPK1 P28482 1/20 0.35
CHRM2 P08172 3/20 0.34
CHRM4 P08173 3/20 0.34
CHRM3 P20309 3/20 0.34
PIK3CD O00329 1/20 0.33
RECQL P46063 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
DPP4 P27487 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20090738 1.00 ALDH1A1 (0.45) ALDH1A1CYP1A2CYP3A4CYP2C19CHRM1
SCHEMBL7849306 0.93 ALDH1A1 (0.49) ALDH1A1CYP1A2CYP3A4CYP2C19CHRM1
SCHEMBL19423892 0.84 ALDH1A1 (0.38) ALDH1A1CYP1A2CYP3A4CYP2C19CHRM1
SCHEMBL15851267 0.78 ALDH1A1 (0.43) ALDH1A1CYP1A2CYP3A4CYP2C19CHRM1
SCHEMBL15851271 0.78 ALDH1A1 (0.43) ALDH1A1CYP1A2CYP3A4CYP2C19CHRM1
SCHEMBL16866231 0.78 LMNA (0.52) ALDH1A1CYP1A2CYP3A4CYP2C19CHRM1
SCHEMBL18347994 0.78 ALDH1A1 (0.43) ALDH1A1CYP1A2CYP3A4CYP2C19CHRM1
SCHEMBL16920563 0.78 LMNA (0.52) ALDH1A1CYP1A2CYP3A4CYP2C19CHRM1
SCHEMBL24735809 0.77 RECQL (0.50) ALDH1A1CYP1A2CYP3A4CYP2C19CHRNB2
SCHEMBL15196701 0.77 ALDH1A1 (0.42) ALDH1A1CYP1A2CYP3A4CYP2C19CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278998-A1 Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof 280 BIO, INC. (US) 2023-09-07 US disclosed
US-10005792-B2 Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors CTXT PTY. LTD. (AU) 2018-06-26 US disclosed
US-9988391-B2 TBK/IKK inhibitor compounds and uses thereof MERCK PATENT GMBH (DE) 2018-06-05 US disclosed
US-9988391-B2 TBK/IKK inhibitor compounds and uses thereof MERCK PATENT GMBH (DE) 2018-06-05 US disclosed
US-20180111934-A1 HETEROCYCLIC MORPHINAN DERIVATIVES AND USE THEREOF PURDUE PHARMA L.P. 2018-04-26 US disclosed
US-20180111934-A1 HETEROCYCLIC MORPHINAN DERIVATIVES AND USE THEREOF PURDUE PHARMA L.P. 2018-04-26 US disclosed
US-20170313713-A1 AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS CTXT PTY. LTD. (AU) 2017-11-02 US disclosed
US-20170298075-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS CTXT PTY. LTD. (AU) 2017-10-19 US disclosed
US-20170283407-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS CTXT PTY. LTD. (AU) 2017-10-05 US disclosed
US-20160376283-A1 TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2016-12-29 US disclosed
US-9403824-B2 Pyridonemorphinan analogs and biological activity on opioid receptors PURDUE PHARMA L.P. (US) 2016-08-02 US disclosed
US-9340542-B2 Propellane-based compounds and the use thereof PURDUE PHARMA L.P. (US) 2016-05-17 US disclosed
US-20150203494-A1 PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS PURDUE PHARMA L.P. 2015-07-23 US disclosed
US-20150183787-A1 PROPELLANE-BASED COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2015-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10005792-B2 Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors PRMT5, PRMT1, PRMT3 ALDH1A1 2987/4885CYP1A2 767/4885CYP3A4 1248/4885
US-20180111934-A1 HETEROCYCLIC MORPHINAN DERIVATIVES AND USE THEREOF OPRM1, OPRL1, OPRD1 ALDH1A1 626/4885CYP1A2 82/4885CYP3A4 80/4885
US-20150183787-A1 PROPELLANE-BASED COMPOUNDS AND THE USE THEREOF OPRL1, OPRK1, OPRD1 ALDH1A1 214/4885CYP1A2 191/4885CYP3A4 402/4885
US-20170313713-A1 AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS PRMT5, PRMT1, PRMT3 ALDH1A1 2910/4885CYP1A2 820/4885CYP3A4 1299/4885
US-20150203494-A1 PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS OPRM1, OPRK1, OPRL1 ALDH1A1 704/4885CYP1A2 204/4885CYP3A4 460/4885
US-20170298075-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS PRMT5, PRMT1, PRMT3 ALDH1A1 4190/4885CYP1A2 1959/4885CYP3A4 1562/4885
US-20170283407-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS PRMT5, PRMT3, PRMT1 ALDH1A1 4354/4885CYP1A2 1990/4885CYP3A4 1593/4885
US-20230278998-A1 Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof PARG, CYP3A5, CYP11B1 ALDH1A1 749/4885CYP1A2 41/4885CYP3A4 20/4885
US-20160376283-A1 TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF NFKBIA, TBKBP1, TBK1 ALDH1A1 4646/4885CYP1A2 3277/4885CYP3A4 2421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.